IXICO rises amid tie-up with ‘leading' pharma'

It is expected to make a material contribution to IXICO’s revenue in the next 12-18 months

A digital healthcare platform will help monitor and manage treatment for multiple sclerosis

IXICO (LON:IXI) advanced in early deals after revealing a strategic collaboration with an un-named leading pharmaceutical company and independent expert clinical centres.

The collaboration is expected to see IXICO develop an adapted version of its digital healthcare platform to help monitor and manage approved pharmaceutical treatments for multiple sclerosis in the EU and Canada.

It is expected to start this month, and the anticipated table sees the platform in a clinical setting in 2016.

Chief executive Professor Derek Hill expects the collaboration to make a material contribution to IXICO’s revenue in the next 12-18 months, which he says underpins the group’s confidence in meeting market expectations.

John Hall, IXICO senior vice president of commercial operations, meanwhile, said: “We are delighted that this new collaboration will expand the use of our Assessa platform into another clinical area alongside currently approved treatments, further extending the reach and application of our technology and expertise.”

In early deals, IXICO shares gained up to 8% to trade at 33p each.

Quick facts: IXICO PLC


Price: 79.75 GBX

Market Cap: £38.4 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Ixico seeing success with a number of contracts awarded covering multiple...

Ixico plc Chief Commercial Officer Lammert Albers joined Steve Darling from Proactive to share news the Clinical Research Organization has awarded the company, on behalf of their biopharmaceutical sponsor,  a 6-figure deal to conduct a Phase II Alzheimer’s disease clinical trial.  Albers...

4 days, 8 hours ago

2 min read